Source: Annual Congress 2003 - Miscellaneous respiratory infections in children
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. M. D. Domenico, P. M. D. Francesco (Palmi, San Giovanni, Italy). Severe adverse reactions in asthmatic children treated with specific immunotherapy(s.I.T.). Eur Respir J 2003; 22: Suppl. 45, 2025

Member's Comments

No comment yet.

Related content which might interest you: Montelukast: neuropsychiatric adverse drug reactions in Tunisian asthmatic children Source: International Congress 2018 – Paediatric asthma: new insights in its prevalence, treatment and treatment failure Year: 2018 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Severe asthma in children Source: CME Online 2011 Year: 2011 Adherence to inhaled controller therapy and local adverse events in children with asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Severe asthma in children Source: International Congress 2015 – Fingerprinting severe asthma Year: 2015 Lack of cataracts and other localized adverse events in children treated with nebulized budesonide inhalation suspension Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001 Possible neuropsychic adverse reactions with montelukast in childhood asthma Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001 Mild asthma. The problems of control Source: Eur Respir J 2007; 30: Suppl. 51, 71s Year: 2007 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Should patients with life-threatening severe asthma be intubated? Source: Virtual Congress 2021 – PDW End of life care for the elderly asthmatic and COPD patients Year: 2021 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Monitoring asthma in children: treatment-related issues Source: International Congress 2014 – Monitoring asthma in children: results of the ERS Task Force Year: 2014 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001